Reginald  Seeto net worth and biography

Reginald Seeto Biography and Net Worth

Insider of CareDx
Dr. Seeto is an experienced leader and has held executive leadership roles in both biotech and large pharma and across a broad range of functions. Before joining CareDx, Dr. Seeto was Chief Operating Officer at Ardelyx leading pre-launch efforts for tenapanor and corporate development where he completed a series of partnerships. Prior to this, Dr. Seeto worked at AstraZeneca/Medimmune and was a member of the MedImmune Executive Team. His responsibilities included leading corporate development and strategy, global strategic marketing and portfolio management for all therapeutic areas, as well as a country leadership role at AstraZeneca in Thailand. He started his career as a physician, during which time he performed a medical rotation in a renal transplant unit, before joining McKinsey and Company.

What is Reginald Seeto's net worth?

The estimated net worth of Reginald Seeto is at least $3.66 million as of October 2nd, 2023. Dr. Seeto owns 479,164 shares of CareDx stock worth more than $3,660,813 as of April 25th. This net worth evaluation does not reflect any other assets that Dr. Seeto may own. Learn More about Reginald Seeto's net worth.

How do I contact Reginald Seeto?

The corporate mailing address for Dr. Seeto and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected]. Learn More on Reginald Seeto's contact information.

Has Reginald Seeto been buying or selling shares of CareDx?

Reginald Seeto has not been actively trading shares of CareDx within the last three months. Most recently, Reginald Seeto sold 2,818 shares of the business's stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $6.91, for a transaction totalling $19,472.38. Following the completion of the sale, the insider now directly owns 479,164 shares of the company's stock, valued at $3,311,023.24. Learn More on Reginald Seeto's trading history.

Who are CareDx's active insiders?

CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.

Are insiders buying or selling shares of CareDx?

In the last twelve months, insiders at the sold shares 11 times. They sold a total of 44,448 shares worth more than $405,276.89. The most recent insider tranaction occured on October, 2nd when insider Reginald Seeto sold 2,818 shares worth more than $19,472.38. Insiders at CareDx own 4.2% of the company. Learn More about insider trades at CareDx.

Information on this page was last updated on 10/2/2023.

Reginald Seeto Insider Trading History at CareDx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2023Sell2,818$6.91$19,472.38479,164View SEC Filing Icon  
9/5/2023Sell2,819$9.49$26,752.31481,982View SEC Filing Icon  
8/14/2023Sell576$8.89$5,120.64484,801View SEC Filing Icon  
8/2/2023Sell2,819$11.35$31,995.65486,051View SEC Filing Icon  
7/13/2023Sell5,260$10.33$54,335.80488,870View SEC Filing Icon  
7/3/2023Sell2,818$8.48$23,896.64498,055View SEC Filing Icon  
6/28/2023Sell14,268$8.76$124,987.68500,873View SEC Filing Icon  
6/2/2023Sell2,819$8.13$22,918.47532,177View SEC Filing Icon  
5/2/2023Sell2,819$8.12$22,890.28534,996View SEC Filing Icon  
4/3/2023Sell2,818$8.95$25,221.10537,815View SEC Filing Icon  
3/2/2023Sell2,819$15.88$44,765.72540,633View SEC Filing Icon  
2/9/2023Sell11,094$16.13$178,946.22551,940View SEC Filing Icon  
2/7/2023Sell3,069$16.40$50,331.60563,034View SEC Filing Icon  
2/2/2023Sell2,819$17.15$48,345.85575,803View SEC Filing Icon  
1/3/2023Sell2,818$11.69$32,942.42268,906View SEC Filing Icon  
3/21/2022Sell2,888$40.43$116,761.84View SEC Filing Icon  
3/1/2022Sell3,153$38.62$121,768.86View SEC Filing Icon  
2/9/2022Sell2,550$45.00$114,750.00View SEC Filing Icon  
2/4/2022Sell4,988$40.34$201,215.92View SEC Filing Icon  
2/1/2022Sell814$42.13$34,293.82View SEC Filing Icon  
1/18/2022Sell1,719$40.07$68,880.33View SEC Filing Icon  
8/27/2021Sell658$80.00$52,640.00View SEC Filing Icon  
7/8/2021Sell5,994$85.67$513,505.98136,748View SEC Filing Icon  
6/28/2021Sell13,212$95.75$1,265,049.00135,618View SEC Filing Icon  
3/1/2021Sell10,704$85.45$914,656.80
12/18/2020Sell8,363$68.01$568,767.63114,745View SEC Filing Icon  
See Full Table

Reginald Seeto Buying and Selling Activity at CareDx

This chart shows Reginald Seeto's buying and selling at CareDx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CareDx Company Overview

CareDx logo
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $7.56
Low: $7.53
High: $7.80

50 Day Range

MA: $9.62
Low: $7.56
High: $12.08

2 Week Range

Now: $7.56
Low: $4.80
High: $12.93

Volume

555,244 shs

Average Volume

893,064 shs

Market Capitalization

$391.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42